Home » Newsletters » BioWorld Science

BioWorld Science

July 26, 2022

View Archived Issues

THR-beta agonists described by Shanghai Kunheng Pharmaceutical Technology, Kunming Pharmaceutical

Shanghai Institute of Materia Medica identifies new nagilactone derivatives

New SOS-1 inhibitors discovered at Chengdu Baiyu Pharmaceutical

Discovery of allosteric mutant-selective EGFR inhibitor for the treatment of NSCLC

Sarissa presents new DNA repair protein RAD51 homolog 1 inhibitors

New CDC7 inhibitors synthesized at Medshine Discovery

FDA accepts IND for HOOKIPA's arenaviral immunotherapy HB-300 for metastatic CRPC

Altamira Therapeutics to develop OligoPhore-based AM-411 for rheumatoid arthritis

PsychoGenics to evaluate preclinical antiseizure efficacy of IAMA's selective NKCC1 inhibitors

Oryzon collaborates with CMTRF to evaluate HDAC6 inhibitors for Charcot-Marie-Tooth disease

RNF31 as a novel therapeutic target for immunotherapy-refractory cancers

New compound advances anoctamin-1 inhibition for analgesia

Nonessential but critical, tyrosine plays key role in nutrient sensing

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
ADPD 2026: Can we prevent dementia? Scientists quantify it
BioWorld
Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026